More information on this family may be found on the IUPHAR-DB family and introduction pages.
Dopamine receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Dopamine Receptors, [24]) are commonly divided into D1-like (D1 and D5) and D2-like (D2, D3 and D4) families, where the endogenous agonist is dopamine. quinpirole is an agonist with selectivity for D2-like receptors.
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
Receptors 
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
Beaulieu, JM; Gainetdinov, RR. (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev., 63 (1): 182-217. [PMID:21303898]
Björklund, A; Dunnett, SB. (2007) Fifty years of dopamine research. Trends Neurosci., 30 (5): 185-7. [PMID:17397938]
Björklund, A; Dunnett, SB. (2007) Dopamine neuron systems in the brain: an update. Trends Neurosci., 30 (5): 194-202. [PMID:17408759]
Carlsson, A; Carlsson, ML. (2008) Adaptive properties and heterogeneity of dopamine D(2) receptors - pharmacological implications. Brain Res Rev, 58 (2): 374-8. [PMID:18511124]
De Mei, C; Ramos, M; Iitaka, C; Borrelli, E. (2009) Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol, 9 (1): 53-8. [PMID:19138563]
Giorgioni, G; Piergentili, A; Ruggieri, S; Quaglia, W. (2008) Dopamine D5 receptors: a challenge to medicinal chemists. Mini Rev Med Chem, 8 (10): 976-95. [PMID:18782049]
Hasbi, A; O'Dowd, BF; George, SR. (2010) Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms. Curr Opin Pharmacol, 10 (1): 93-9. [PMID:19897420]
Hoebel, BG; Avena, NM; Rada, P. (2007) Accumbens dopamine-acetylcholine balance in approach and avoidance. Curr Opin Pharmacol, 7 (6): 617-27. [PMID:18023617]
Horowski, R. (2007) A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view. J Neural Transm, 114 (1): 127-34. [PMID:16897593]
Iversen, SD; Iversen, LL. (2007) Dopamine: 50 years in perspective. Trends Neurosci., 30 (5): 188-93. [PMID:17368565]
Joyce, JN; Millan, MJ. (2007) Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr Opin Pharmacol, 7 (1): 100-5. [PMID:17174156]
Le Foll, B; Gallo, A; Le Strat, Y; Lu, L; Gorwood, P. (2009) Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol, 20 (1): 1-17. [PMID:19179847]
Maggio, R; Millan, MJ. (2010) Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol, 10 (1): 100-7. [PMID:19896900]
Ohara, K. (2007) The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31 (2): 469-74. [PMID:17184889]
Rollo, CD. (2009) Dopamine and aging: intersecting facets. Neurochem. Res., 34 (4): 601-29. [PMID:18841466]
Rolls, ET; Loh, M; Deco, G; Winterer, G. (2008) Computational models of schizophrenia and dopamine modulation in the prefrontal cortex. Nat. Rev. Neurosci., 9 (9): 696-709. [PMID:18714326]
Rondou, P; Haegeman, G; Van Craenenbroeck, K. (2010) The dopamine D4 receptor: biochemical and signalling properties. Cell. Mol. Life Sci., 67 (12): 1971-86. [PMID:20165900]
Schwartz J-C et al. (1998) Dopamine Receptors. in The IUPHAR Compendium of Receptor Characterization and Classification Edited by Girdlestone D IUPHAR Media. 141-151
Scott, L; Aperia, A. (2009) Interaction between N-methyl-D-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity. Neuroscience, 158 (1): 62-6. [PMID:19000746]
Stanwood, GD. (2008) Protein-protein interactions and dopamine D2 receptor signaling: a calcium connection. Mol. Pharmacol., 74 (2): 317-9. [PMID:18511653]
Thomas, MJ; Kalivas, PW; Shaham, Y. (2008) Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br. J. Pharmacol., 154 (2): 327-42. [PMID:18345022]
Undieh, AS. (2010) Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol. Ther., 128 (1): 37-60. [PMID:20547182]
Wood, MD; Wren, PB. (2008) Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders. Prog. Brain Res., 172: 213-30. [PMID:18772035]
1. Akunne, HC; Towers, P; Ellis, GJ; Dijkstra, D; Wikström, H; Heffner, TG; Wise, LD; Pugsley, TA. (1995) Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci., 57 (15): 1401-10. [PMID:7674830]
2. Andersen, P. H. and Jansen, J. A. (1990) Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol, 188: 335-347. [PMID:1973652]
3. Dearry, A., Gringrich, J. A., Falardeau, P., Fremeau, R. T., Bates, M. D. and Caron, M. G. (1990) Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature, 347: 72-76. [PMID:2144334]
4. Freedman, S. B., Patel, S., Marwood, R., Emms, F., Seabrook, G. R., Knowles, M. R. and McAllister, G. (1994) Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther, 268: 417-426. [PMID:8301582]
5. Hidaka, K; Matsumoto, M; Tada, S; Tasaki, Y; Yamaguchi, T. (1995) Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors. Neurosci. Lett., 186 (2-3): 145-8. [PMID:7777184]
6. Kortagere, S., Gmeiner, P., Weinstein, H. and Schetz, J. A. (2004) Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common receptor microdomain. Mol Pharmacol, 66: 1491-1499. [PMID:15448188]
7. Kulagowski, JJ; Broughton, HB; Curtis, NR; Mawer, IM; Ridgill, MP; Baker, R; Emms, F; Freedman, SB; Marwood, R; Patel, S; et al.. (1996) 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J. Med. Chem., 39 (10): 1941-2. [PMID:8642550]
8. Köhler, C; Hall, H; Ogren, SO; Gawell, L. (1985) Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem. Pharmacol., 34 (13): 2251-9. [PMID:4015674]
9. McCall, RB; Lookingland, KJ; Bédard, PJ; Huff, RM. (2005) Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J. Pharmacol. Exp. Ther., 314 (3): 1248-56. [PMID:15980060]
10. Millan, M. J., Audinot, V., Rivet, J. M., Gobert, A., Vian, J., Prost, J. F., Spedding, M. and Peglion, J. L. (1994) S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol, 260: R3-R5. [PMID:7988633]
11. Millan, M. J., Gobert, A., Newman-Tancredi, A., Lejeune, F., Cussac, D., Rivet, J. M., Audinot, V., Dubuffet, T. and Lavielle, G. (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther, 293: 1048-1062. [PMID:10869410]
12. Millan, M. J., Peglion, J. L., Vian, J., Rivet, J. M., Brocco, M., Gobert, A., Newman-Tancredi, A., Dacquet, C., Bervoets, K. and Girardon, S. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther, 275: 885-898. [PMID:7473180]
13. Moreland, R. B., Patel, M., Hsieh, G. C., Wetter, J. M., Marsh, K. and Brioni, J. D. (2005) A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol Biochem Behav, 82: 140-147. [PMID:16153699]
14. Patel, S., Patel, S., Marwood, R., Emms, F., Marston, D., Leeson, P. D., Curtis, N. R., Kulagowski, J. J. and Freedman, S. B. (1996) Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol, 50: 1658-1664. [PMID:8967990]
15. Primus, RJ; Thurkauf, A; Xu, J; Yevich, E; McInerney, S; Shaw, K; Tallman, JF; Gallagher, DW. (1997) II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1. J. Pharmacol. Exp. Ther., 282 (2): 1020-7. [PMID:9262371]
16. Pugsley, T. A., Davis, M. D., Akunne, H. C., MacKenzie, R. G., Shih, Y. H., Damsma, G., Wikstrom, H., Whetzel, S. Z., Georgic, L. M. and Cooke, L. W. (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther, 275: 1355-1366. [PMID:8531103]
17. Reavill, C., Taylor, S. G., Wood, M. D., Ashmeade, T., Austin, N. E., Avenell, K. Y., Boyfield, I., Branch, C. L., Cilia, J., Coldwell, M. C., Hadley, M. S., Hunter, A. J., Jeffrey, P., Jewitt, F., Johnson, C. N., Jones, D. N., Medhurst, A. D., Middlemiss, D. N., Nash, D. J., Riley, G. J., Routledge, C., Stemp, G., Thewlis, K. M., Trail, B., Vong, A. K. and Hagan, J. J. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther, 294: 1154-1165. [PMID:10945872]
18. Ricci, A; Amenta, F. (1994) Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J. Neuroimmunol., 53 (1): 1-7. [PMID:8051291]
19. Ricci, A; Veglio, F; Amenta, F. (1995) Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT. J. Neuroimmunol., 58 (2): 139-44. [PMID:7759603]
20. Rowley, M; Broughton, HB; Collins, I; Baker, R; Emms, F; Marwood, R; Patel, S; Patel, S; Ragan, CI; Freedman, SB; et al.. (1996) 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J. Med. Chem., 39 (10): 1943-5. [PMID:8642551]
21. Sautel, F., Griffon, N., Lévesque, D., Pilon, C., Schwartz, J. C. and Sokoloff, P. (1995) A functional test identifies dopamine agonists selective for D3versus D2receptors. Neuroreport, 6: 329-332. [PMID:7756621]
22. Sautel, F., Griffon, N., Sokoloff, P., Schwartz, J. C., Launay, C., Simon, P., Costentin, J., Schoenfelder, A., Garrido, F., Mann, A. et al.. (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther., 275: 1239-1246. [PMID:8531087]
23. Schlachter, S. K., Poel, T. J., Lawson, C. F., Dinh, D. M., Lajiness, M. E., Romero, A. G., Rees, S. A., Duncan, J. N. and Smith, M. W. (1997) Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor. Eur J Pharmacol, 322: 283-286. [PMID:9098699]
24. Schwartz JC, Carlsson A, Caron M, Scatton B, Civelli O, Kebabian JW , Langer SZ, Sedvall G, Seeman P, Spano PF, Sokoloff P, Van Tol H. (1998) Dopamine receptors. in The IUPHAR Compendium of Receptor Characterization and Classification Edited by Girdlestone D IUPHAR media. 141–151
25. Sokoloff, P., Andrieux, M., Besançon, R., Pilon, C., Martres, M.-P., Giros, B. and Schwartz, J.-C. (1992) Pharmacology of human D3 dopamine receptor expressed in a mammalian cell line : comparison with D2 receptor. Eur. J. Pharmacol., 225: 331-337. [PMID:1354163]
26. Sunahara, R. K., Guan, H. C., O'Dowd, B. F., Seeman, P., Laurier, L. G., Ng, G., George, S. R., Torchia, J., Van Tol, H. H. and Niznik, H. B. (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature, 350: 614-619. [PMID:1826762]
27. Tiberi, M. and Caron, M. G. (1994) High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J. Biol. Chem., 269: 27925-27931. [PMID:7525564]
28. Tice, MA; Hashemi, T; Taylor, LA; Duffy, RA; McQuade, RD. (1994) Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacol. Biochem. Behav., 49 (3): 567-71. [PMID:7862709]
29. Zhen, J; Antonio, T; Dutta, AK; Reith, ME. (2010) Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors. J. Neurosci. Methods, 188 (1): 32-8. [PMID:20122961]
30. Zhou, Q. Z., Grandy, D. K., Thambi, L., Kushner, J. A., Van Tol, H. H., Cone, R., Pribnow, D., Salon, J. and Bunzow, J. (1990) Cloning and expression of human and rat D1 dopamine receptors. Nature, 347: 76-86. [PMID:2168520]
|
 @GuidetoPHARM  Like us on Facebook Privacy and Cookie Policy |
The selectivity of many of these agents is less than two orders of magnitude. [3H]raclopride exhibits similar high affinity for D2 and D3 receptors (low affinity for D4), but has been used to label D2 receptors in the presence of a D3-selective antagonist. [3H]7-OH-DPAT has similar affinity for D2 and D3 receptors, but labels only D3 receptors in the absence of divalent cations. The pharmacological profile of the D5 receptor is similar to, yet distinct from, that of the D1 receptor. The splice variants of the D2 receptor are commonly termed D2S and D2L (short and long). The DRD4 gene encoding the D4 receptor is highly polymorphic in humans, with allelic variations of the protein from amino acid 387 to 515.